
The US Food and Drug Administration, FDA, has again postponed its deadline for responding to Eli Lilly's application for the authorization of Olumiant, which is an eczema treatment for adults.
Eli Lilly and Incyte, the two firms collaborating over the drug, have therefore announced that the FDA will not respond in line with its original deadline, which was the third quarter of this year. They have not revealed when they now expect a response.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app